Armitage JO - Search Results

1

Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.

Coiffier B, Gisselbrecht C, Vose JM, Tilly H, Herbrecht R, Bosly A, Armitage JO. Coiffier B, et al. Among authors: armitage jo. J Clin Oncol. 1991 Feb;9(2):211-9. doi: 10.1200/JCO.1991.9.2.211. J Clin Oncol. 1991. PMID: 1703226

2

The present status of therapy for patients with aggressive non-Hodgkin's lymphoma.

Vose JM, Armitage JO. Vose JM, et al. Among authors: armitage jo. Ann Oncol. 1991 Feb;2 Suppl 2:171-6. doi: 10.1007/978-1-4899-7305-4_27. Ann Oncol. 1991. PMID: 2049315 Free article. Review.

3

Report of the first workshop on prognostic factors in large-cell lymphomas.

Coiffier B, Shipp MA, Cabanillas F, Crowther D, Armitage JO, Canellos GP. Coiffier B, et al. Among authors: armitage jo. Ann Oncol. 1991 Feb;2 Suppl 2:213-7. doi: 10.1007/978-1-4899-7305-4_34. Ann Oncol. 1991. PMID: 1675583 Free article. No abstract available.

4

Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen.

Weekes CD, Vose JM, Lynch JC, Weisenburger DD, Bierman PJ, Greiner T, Bociek G, Enke C, Bast M, Chan WC, Armitage JO; Nebraska Lymphoma Study Group. Weekes CD, et al. Among authors: armitage jo. J Clin Oncol. 2002 Feb 15;20(4):1087-93. doi: 10.1200/JCO.2002.20.4.1087. J Clin Oncol. 2002. PMID: 11844834 Clinical Trial.

5

Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.

Vose JM, Sharp G, Chan WC, Nichols C, Loh K, Inwards D, Rifkin R, Bierman PJ, Lynch JC, Weisenburger DD, Kessinger A, Armitage JO. Vose JM, et al. Among authors: armitage jo. J Clin Oncol. 2002 May 1;20(9):2344-52. doi: 10.1200/JCO.2002.09.138. J Clin Oncol. 2002. PMID: 11981006 Clinical Trial.

6

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.

Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC, Armitage JO. Vose JM, et al. Among authors: armitage jo. J Clin Oncol. 2005 Jan 20;23(3):461-7. doi: 10.1200/JCO.2005.05.117. Epub 2004 Nov 8. J Clin Oncol. 2005. PMID: 15534357 Clinical Trial.

7

To Surveil or Not to Surveil.

Armitage JO, Vose JM. Armitage JO, et al. J Clin Oncol. 2015 Dec 1;33(34):3983-4. doi: 10.1200/JCO.2015.63.5946. Epub 2015 Oct 5. J Clin Oncol. 2015. PMID: 26438116 No abstract available.

8

Clinical applications of hematopoietic growth factors.

Vose JM, Armitage JO. Vose JM, et al. Among authors: armitage jo. J Clin Oncol. 1995 Apr;13(4):1023-35. doi: 10.1200/JCO.1995.13.4.1023. J Clin Oncol. 1995. PMID: 7535842 Review.

9

Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.

Bennett CL, Armitage JL, Armitage GO, Vose JM, Bierman PJ, Armitage JO, Anderson JR. Bennett CL, et al. Among authors: armitage jo, armitage jl, armitage go. J Clin Oncol. 1995 Apr;13(4):969-73. doi: 10.1200/JCO.1995.13.4.969. J Clin Oncol. 1995. PMID: 7707125

10

Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.

Vaughan WP, Kris E, Vose J, Bierman PJ, Gwilt P, Armitage JO. Vaughan WP, et al. Among authors: armitage jo. J Clin Oncol. 1995 May;13(5):1089-95. doi: 10.1200/JCO.1995.13.5.1089. J Clin Oncol. 1995. PMID: 7738614 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

591 results

Search Page

Filters